Coordinating Center for Systems Biology Approach to the Mechanisms of Tuberculosis (TB) Latency and Reactivation (R01)

The summary for the Coordinating Center for Systems Biology Approach to the Mechanisms of Tuberculosis (TB) Latency and Reactivation (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Coordinating Center for Systems Biology Approach to the Mechanisms of Tuberculosis (TB) Latency and Reactivation (R01): Purpose. The National Heart, Lung, and Blood Institute solicits applications under this funding opportunity announcement (FOA) to participate as Data Coordinating Center for the NHLBI Systems Biology Approach to the Mechanisms of Tuberculosis (TB) Latency and Reactivation program. The NHLBI Systems Biology Approach to TB Program will include multiple TB Systems Biology Centers and one Data Coordinating Center. This program is designed to investigate the mechanisms of latency and the reactivation of tuberculosis in the host using integrated systems biology approaches. Systems biology is defined in many ways. For the purposes of this FOA we are using a definition found on the MIT CSBi website a research program that links biologists, computer scientists, and engineers in a multi disciplinary approach to the systematic analysis of complex biological phenomena. The studies should include multiscale computational modeling and focus on host lung responses to Mycobacterium tuberculosis (Mtb) and host-microbial interactions that drive latency and reactivation in humans. To build the theoretical models human and animal data should be utilized. The studies should integrate the data obtained from omic approaches with biological/immunological data. The models should be such that they can be tested in humans or non-human primates. The use of human samples and or data is required. However, the additional use of animal models/data in building and testing the models is encouraged to enable a better understanding of latency and reactivation in humans. This FOA solicits applications for the Data Coordinating Center and runs in parallel with a separate FOA that solicits applications for up to four TB Systems Biology Centers (see RFA-HL-10-015)

Federal Grant Title:	Coordinating Center for Systems Biology Approach to the Mechanisms of Tuberculosis (TB) Latency and Reactivation (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-10-022
Type of Funding:	Grant
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	Mar 24, 2010
Original Application Deadline:	Mar 24, 2010
Posted Date:	Dec 09, 2009
Creation Date:	Dec 09, 2009
Archive Date:	Apr 24, 2010
Total Program Funding:	$3,450,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)